|
|
||||||||
J Thorac Cardiovasc Surg 2002;124:479-485
© 2002 The American Association for Thoracic Surgery
Surgery for Congenital Heart Disease (CHD) |
From the Division of Cardiothoracic Surgery, University of California, San Francisco, Calif.
Read at the Eighty-first Annual Meeting of The American Association for Thoracic Surgery, San Diego, Calif, May 6-9, 2001.
Received for publication May 14, 2001. Revisions requested Aug 3, 2001; revisions received Sept 10, 2001. Accepted for publication Sept 18, 2001. Address for reprints: R. Kirk Riemer, PhD, Stanford University, Department of Cardiothoracic Surgery, Falk CVRB-CV116C, Stanford, CA 94305-5407 (E-mail: Riemerk{at}Stanford.edu).
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Prior observations have demonstrated widespread pulmonary vascular remodeling after CPA. Histologic analyses of lung tissue after CPA reveal the proliferation of dilated microvascular structures.
4,5 Recent findings from this animal model suggest that inhibited pulmonary angiotensin-converting enzyme expression and angiotensin II production may contribute to the chronic pulmonary vasodilation after CPA.
6
Unfortunately, the physiologic and molecular basis for this abnormal pulmonary vascular remodeling remains poorly understood. CPA results in a number of potentially relevant modifications to the pulmonary circulation. Exclusion of inferior vena caval effluent is likely the most significant consequence of CPA. Another major physiologic alteration caused by CPA is reduced pulmonary blood flow. In this study we examined the pulmonary expression of oxidative stress-inducible and angiogenic proteins after CPA using our ovine model. To exclude changes in gene expression caused by reduced pulmonary blood flow, we performed similar analysis on age-matched lambs that underwent pulmonary artery banding (PAB). Because PAB does not result in the formation of pulmonary AVMs, changes in patterns of gene expression specific to CPA will yield valuable insight into the molecular mechanisms responsible for the development of such malformations.
This study examines the role of hypoxia-inducible factor 1
(HIF-1
) in the development of pulmonary arteriovenous shunting. HIF-1
has been implicated in the pathophysiology of several pulmonary vascular disorders, including pulmonary hypertension.
7 HIF-1
upregulates the expression of numerous genes involved in vascular remodeling by binding to a consensus nucleotide sequence known as the HIF-1
-responsive element.
8 Some of these genes include those coding for the oxidative stress-associated factors hemoxygenase 1 (HO1) and glucose transporter 1 (GLUT1), as well as the angiogenic gene vascular endothelial growth factor (VEGF) and its receptor, Flt-1. This study examines the early pulmonary expression (at 2 and 5 weeks after the operation) of these HIF-1
-inducible genes, as well as P-selectin (CD62), an HIF-1
-independent marker of endothelial activation, after CPA and PAB.
| Methods |
|---|
|
|
|---|
|
A third group of lambs of the same age served as sham-operated control animals (n = 6). The preparation and dissection was the same as that described for the Glenn cohort. The RPA was occluded with a vascular clamp for 30 minutes. After this time, the clamp was removed, and the chest was closed as described above.
All animals received humane care in compliance with the "Principles of Laboratory Animal Care," formulated by the National Society of Medical Research, and the "Guide for the Care and Use of Laboratory Animals," prepared by the Institute of Laboratory Animal Resources, National Research Council, and published by the National Academy Press, revised 1996. The protocol was approved by the Committee on Animal Research at the University of California, San Francisco.
Echocardiography
Pulmonary AV shunting was demonstrated by means of bubble contrast echocardiography. Epicardial echocardiography was performed on each animal after median sternotomy. In the CPA cohort 5 mL of a saline solution-blood mixture was agitated to produce bubbles and then injected sequentially into the SVC and inferior vena cava. In the PAB group a similar bubbled saline solution-blood mixture was injected into each pulmonary artery sequentially. The appearance of bubbles in the left atrium within 5 cardiac cycles after SVC injection indicates AV shunting.
9
Tissue harvest
Lambs were killed at 2 and 5 weeks after the operation to obtain tissue for analysis. Animals were intubated and mechanically ventilated. After median sternotomy, the lambs were anticoagulated with sodium heparin (300 U/kg). The lambs were then put to death with an infusion of sodium pentobarbital, the lungs were removed, and samples were snap-frozen in liquid nitrogen.
Western blot analysis
Specimens of right lung tissue from CPA and control groups and left lung tissue from the PAB cohort were obtained as described above. Specimens were homogenized, and proteins were extracted as previously described.
10 Proteins were then transferred to a polyvinylidene difluoride membrane (Amersham Pharmacia Biotech Inc, Piscataway, NJ). The membrane was soaked in Tris-buffered saline solution (100 mM Tris-HCl pH 7.5 and 150 mM NaCl) containing 5% nonfat powdered milk and 0.1% Tween-20 to block nonspecific binding. The membrane was then incubated overnight at 4°C with the following primary antisera at the specified dilutions: HIF-1
, 1:1000 (BD Transduction Laboratories, Lexington, Ky); VEGF, 1:200 (Santa Cruz Biotechnology, Santa Cruz, Calif); GLUT-1, 1:200 (Flt, Santa Cruz Biotechnology); HO-1, 1:200 (Santa Cruz Biotechnology); and CD62, 1:200 (Research Diagnostics, Inc, Flanders, NJ). Blots were washed and incubated for 30 minutes at 4°C with a peroxidase-conjugated secondary antibody (1:20,000 dilution, Vector Laboratories, Inc, Burlingame, Calif). Immunoreactivity was detected with the Supersignal chemiluminescent substrate kit (Pierce Chemical Company, Rockford, Ill). Quantitative assessment of band densities was performed by using scanning densitometry (1D Image Analysis Software; Eastman Kodak Company, Rochester, NY).
Immunohistochemistry
Immunolocalization was performed as previously described.
9 In brief, lung tissue from experimental and control animals at 5 weeks after CPA, PAB, or sham surgery was fixed in Histochoice (Amresco, Inc, Solon, Ohio). Tissue was then paraffin embedded, sectioned at 7 µm, and mounted onto glass slides. Slides were deparaffinized by means of immersion for 6 minutes each in xylene and 100%, 95%, 70%, and 50% ethanol. Slides were washed with Tris-buffered saline solution (50 mmol/L, pH 7.6) and then incubated with 0.5% hydrogen peroxidase with 1 mg/mL of saponin for 30 minutes to quench endogenous peroxidases. Sections were incubated with 4% serum from the host species for the secondary antisera to reduce nonspecific antibody binding. Sections were incubated for 18 hours with a 1:200 dilution of either the CD62 or VEGF primary antisera described above. Visualization of staining was accomplished with the Vectastain elite kit (Vector Laboratories), with diaminobenzidine as the chromogen (DAB kit, Zymed Laboratories, San Francisco, Calif).
Statistical analysis
Data were analyzed with Statview, a commercially available software package (SAS Institute, Inc, Cary, NC). Protein analysis was evaluated with 3 animals at both 2 and 5 weeks in the CPA, PAB, and sham groups for a total of 6 animals in each cohort. Figures include representative Western blot results for each experimental group. Analysis of statistical differences between groups at each time point was performed by means of paired, 2-tailed Student t tests. Significant differences between the experimental and control groups were confirmed by means of analysis of variance. All values are expressed as means ± SD.
| Results |
|---|
|
|
|---|
HIF-1
protein expression after CPA and PAB
HIF-1
was upregulated in lung tissue 4.3 ± 0.10-fold (P < .001) at 2 weeks and increased 3.9 ± 0.16-fold at 5 weeks (P = .003) after CPA. PAB failed to induce increased HIF-1
protein expression at either 2 or 5 weeks after surgical intervention (P > .2, Figure 2).
|
|
|
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
Our results suggest that CPA causes oxidant stress within the pulmonary vasculature. CPA markedly increases the expression of the stress-associated factors, including HIF-1
. Moreover, this phenomenon is not limited to a HIF-1
-specific pathway because CD62 is also upregulated. Enhanced oxidative stress-related signaling was independent of reduced pulmonary blood flow because PAB failed to cause increased expression of any of these genes.
Interestingly, enhanced angiogenic signaling may not play a central role in the formation of pulmonary AVMs because CPA and PAB both increase the expression of VEGF and Flt-1. The early appearance of increased subpleural vascular markings after CPA led us to initially suspect the involvement of an angiogenic stimulus in the development of these AVMs. However, we found the same degree of enhanced subpleural vascularity in the lungs of the sheep that underwent PAB. Yet we found no evidence of formation pulmonary AVMs after PAB in this animal model. Presumably, reduced pulmonary blood flow is the stimulus for the increased expression of these angiogenic factors.
The altered physiology resulting from CPA may cause a change in the redox state of the pulmonary vascular bed. Exclusion of inferior venous drainage from the pulmonary circulation could potentially interrupt the delivery of a mediator of normal vascular development derived from the liver or some other lower body source. This theory is supported by reports of resolution of pulmonary AVMs after the inclusion of inferior venous blood.
11,12 Pulmonary endothelial oxidative stress may result from the lack of this putative protective factor and serve as a stimulus for the pathologic vascular remodeling responsible for arteriovenous shunting. Further work is warranted to fully understand the mechanisms involved in formation of pulmonary AVMs after CPA.
| Appendix: Discussion |
|---|
|
|
|---|
It is my question whether the oxidative stress in patients with well-developed AVM will upregulate the oxidative stress. Another question is whether you think that the upregulated oxidative stress is a fundamental factor in addition to the lack of some substances delivered from the liver and perfused into the lung in development of pulmonary AVMs.
Dr Malhotra. To the first question, oxidative stress probably affects various endothelium-dependent vasodilation mechanisms and probably inhibits regulation of normal vascular tone. I believe it does create a substrate, perhaps for the development of pulmonary AVMs. Unfortunately, I think we still have much work to do on this topic.
Dr Frank Sellke (Boston, Mass). Your hypothesis is that there is a differential expression of these growth factors, such as HIF-1
, and that this is based on oxidative stress. You can measure oxidative stress in the different lung segments. That would really pin down your hypothesis. Have you done that or are you considering doing that?
Dr Malhotra. We have not done that at this time, but that would be an interesting investigation to pursue.
Dr Sellke. Also, I believe you showed that expression of VEGF was increased in the vessel, as opposed to the surrounding tissue.
Dr Malhotra. We have had localization to the endothelium, yes.
Dr Sellke. The VEGF receptors are localized to the endothelium, but VEGF expression is usually increased everywhere. I think that is true in the lung, in the heart, and in skeletal muscle. I am surprised that the expression in your study was localized to the vessel wall. Is that what you found?
Dr Malhotra. Right, that the protein is increased in the vessel wall.
Dr Christian Pizarro (Orlando, Fla). If these animals, after you created the model, were noncyanotic, how do you put together the fact that HIF was induced when I would take it that the saturations were over 90%?
Second, did you look at EGR-1 and the theory that early growth factor is supposed to be induced as rapidly as HIF-1 in patients who have this type of model created?
Third, did you look at different isoforms of VEGF, meaning the short versus the long forms? We know that they are located and express differently, and perhaps you could have looked at some of that.
Dr Malhotra. To explain upregulation of HIF, we do not postulate that it is a hypoxic environment. These lambs were normal healthy lambs that underwent CPA. We do, however, believe that HIF is a detector of redox status in the parenchyma, and the redox status may be altered by the lack of this hepatic factor.
Second, in response to early growth factor, we have just begun to look at that, and therefore that is a very timely point.
In terms of the isoforms, we have only looked at VEGF-165.
| Acknowledgments |
|---|
| Footnotes |
|---|
*Present address: Department of Surgery, University of Texas, Houston, Tex. ![]()
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. B. McElhinney, A. C. Marshall, P. Lang, J. E. Lock, and J. E. Mayer Jr Creation of a Brachial Arteriovenous Fistula for Treatment of Pulmonary Arteriovenous Malformations After Cavopulmonary Anastomosis Ann. Thorac. Surg., November 1, 2005; 80(5): 1604 - 1609. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ikai, R. K. Riemer, X. Ma, O. Reinhartz, F. L. Hanley, and V. M. Reddy Pulmonary expression of the hepatocyte growth factor receptor c-Met shifts from medial to intimal layer after cavopulmonary anastomosis J. Thorac. Cardiovasc. Surg., May 1, 2004; 127(5): 1442 - 1449. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |